Blog

Dr. Gloria Chiu – Progressive Keratoconus and the Cross-Linking Story

“In 2016, the FDA approval of three products for the corneal strengthening procedure known as corneal collagen crosslinking (CXL) changed the paradigm for treatment of progressive keratoconus.” – Dr. Gloria Chiu, Roski Eye Institute Traditionally, the management of keratoconus has been just that, management. Whether it is fitting patients for new lenses, or clinically advancing … Continued

Dr. Michael Greenwood – Leveraging Social Media to Expand Keratoconus Awareness

“Social media is really important for physicians, doctors of any sort, but especially ophthalmology because we are treating these patients with keratoconus who are at a younger age who are active and on social media and they’re looking for information.” – Dr. Michael Greenwood, Vance Thompson Vision Everyone knows that social media platforms are a … Continued

Helping Your Patients Gain #KCConfidence

At Glaukos we take World Keratoconus Day very seriously. It’s not just an opportunity to raise awareness about this debilitating disease, but also a chance to step back and celebrate the progress and positive changes affecting those who have been impacted by keratoconus at one time or another during their lives. Following the FDA approval … Continued

Dr. Katie Greiner – Make That Cross-Linking Referral

“It is my belief that we are doing the patient a disservice to not offer [iLink™ FDA-approved cross-linking] as an option in the repertoire of care for this disease.” – Dr. Katie Greiner, Northeast Ohio Eye Surgeons As the standard of care for patients with progressive keratoconus, iLink FDA-approved cross-linking should be explored as a … Continued

Dr. Neda Shamie – Incorporating Cross-Linking into Your Practice

“I have been performing corneal collagen cross-linking (CXL) for three years and it has resulted in a paradigm shift in the way we treat progressive keratoconus in our practice, mirroring changes in the standard of care throughout the world.” After more than two years of follow-up on patients she has personally treated, Dr. Neda Shamie … Continued

Redefining the Narrative Around Rare Diseases

In the United States, a rare disease is defined as a condition that affects fewer than 200,000 people. Unfortunately, more than 90% of rare diseases do not have an FDA-approved treatment, and most are genetic or have a genetic component. It is estimated that keratoconus, a progressive eye condition in which the cornea weakens and … Continued

Using Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution), Photrexa® (riboflavin 5’-phosphate ophthalmic solution), and the KXL® System, the iLink™ corneal cross-linking procedure from Glaukos is the only FDA-approved therapeutic treatment for patients with progressive keratoconus and corneal ectasia following refractive surgery.*1

[Photrexa IFU/p1/col1/para3/lines1-4]

Indications

Photrexa® Viscous (riboflavin 5’-phosphate in 20% dextran ophthalmic solution) and Photrexa® (riboflavin 5’-phosphate ophthalmic solution) are indicated for use with the KXL System in corneal collagen cross-linking for the treatment of progressive keratoconus and corneal ectasia following refractive surgery.

Important Safety Information

Corneal collagen cross-linking should not be performed on pregnant women.

Ulcerative keratitis can occur. Patients should be monitored for resolution of epethelial defects. The most common ocular adverse reaction was corneal opacity (haze). Other ocular side effects include punctate keratitis, corneal striae, dry eye, corneal epithelium defect, eye pain, light sensitivity, reduced visual acuity, and blurred vision.

These are not all the side effects of the corneal collagen cross-linking treatment. For more information, go www.livingwithkeratoconus.com to obtain the FDA-approved product labeling.

You are encouraged to report all side effects to the FDA. Visit www.fda.gov/medwatch, or call 1-800-FDA-1088.

*Photrexa® Viscous and Photrexa® are manufactured for Avedro. The KXL® System is manufactured by Avedro. Avedro is a wholly owned subsidiary of Glaukos Corporation.

Reference

1. Photrexa [package insert]. Waltham, MA: Glaukos, Inc. 2016